Plain-English translation of NCT03765177 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called , which is a type of living cell therapy designed to help fight blood cancers that have stopped responding to standard chemotherapy or have come back after treatment. The researchers are studying whether this medication is safe and how well it works in patients with certain types of leukemia and lymphoma. The treatment involves infusing specially prepared immune cells into your body to help fight your cancer.
For patients with advanced blood cancers that have returned or become resistant to chemotherapy, treatment options are limited and outcomes are often poor. This trial exists to see whether this new medication can offer hope to patients who have run out of other effective options.
You likely qualify if…
You likely don't qualify if…
You will receive a single intravenous infusion of the medication in the hospital or clinic setting. The trial has two stages: first, the research team will closely monitor the initial 20 patients to confirm the treatment is safe; if it is, up to 80 more patients may be enrolled. After your infusion, you will have follow-up appointments to check your health, monitor for side effects, and assess how well the treatment is working, with particular evaluation at 6 months after receiving the medication.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Canada